Adjuvant endocrine therapy in high-risk HR-positive and HER2-negative early breast cancer
Hormone receptor-positive (HR+) and HER2-negative (HER2−) early breast cancer (EBC) accounts for more than 70% of breast cancer diagnoses. Prognostic assessment is traditionally based on clinical and histological criteria, including tumor size, nodal involvement, histologic grade, and mea...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Academia.edu Journals
2026-02-01
|
| Rangatū: | Academia Oncology |
| Urunga tuihono: | https://www.academia.edu/164870708/Adjuvant_endocrine_therapy_in_high_risk_HR_positive_and_HER2_negative_early_breast_cancer |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|